Delhi HC: Economic Offender Cannot Seek Travel Abroad For Medical Treatment When Available In India  ||  SC: Governors and President Have No Fixed Timeline To Assent To Bills; “Deemed Assent” is Invalid  ||  SC: Assigning a Decree For Specific Performance of a Sale Agreement Does Not Require Registration  ||  SC: No Quota Applies For Judicial Officers in District Judge Posts, Issuing Seniority Guidelines  ||  SC: Interest Rate Disputes Doesn't Fall under Public Policy to Set Aside Arbitration Awards  ||  SC: If Some Offences are Quashed By Compromise, the FIR For The Same Incident Cannot Continue  ||  Supreme Court: TIP is Unreliable if the Witness Saw the Accused Beforehand  ||  Delhi HC: MYAS Not Bound to ‘Rubber-Stamp’ International Federation Choices  ||  AP HC: Fulfilling Rehabilitation Promises to Displaced is State’s Constitutional Obligation  ||  SC: Career Progression to Higher Echelons of Judiciary is Neither a Matter of Right Nor Entitlement    

Finalization of Draft Rules on Sale of Drugs by E-Pharmacies- (Press Information Bureau) (25 Jun 2019)

MANU/PIBU/0667/2019

Law of Medicine

The Government has published draft rules vide G.S.R. 817 (E) dated 28th August 2018 for inviting public/stakeholder comments for amendment to the Drugs and Cosmetics Rules, 1945 for incorporating provisions relating to regulation of sale and distribution of drugs through e-pharmacy. A large number of suggestions/comments have been received from the stakeholders, which are being examined. At the same time, the matter is sub-judice before various Hon'ble High Courts in the country. Therefore, no timeline for finalization of the rules can be provided.

Under the Drugs & Cosmetics Act and Rules, sale of spurious drugs is a punishable offence and State Licensing Authorities are empowered to take action in this regard. Accordingly, the complaints as received, are referred to State Licensing Authorities for taking action as per the provisions of the Act and Rules.

Tags : DRAFT RULES   FINALIZATION   SALE OF DRUGS   E-PHARMACIES  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved